Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study shows promise of CTCs and AR-V7 as biomarkers for radium-223...
-
-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study shows promise of CTCs and AR-V7 as biomarkers for...
-
-- Prostate Circulating Tumor Cells Isolated with TellDx Technology Demonstrates Epigenetic Changes that Silence Immune Surveillance Genes and Spare Proliferation-Associated Genes -- -- Breast Cancer...
-
-- CTCs isolated with TellDx leveraged to assess sensitivity and potential clinical benefit from an alternative tolerable therapeutic option in a select cohort of patients with metastatic breast...
-
--Interrogation of circulating tumor cells (CTCs) shows downregulation of KEAP1 gene promotes resistance to immune checkpoint blockade in melanoma-- --Study provides valuable insights into the...
-
-- TellDx CTC System can be leveraged to monitor efficacy of novel therapeutic agents— --Targeting multiple cadherins with 23C6 can ameliorate cancer metastasis-- -- TellBio has exclusive...
-
-- Single-cell proteomics can elucidate kinase activity in prostate cancer models -- -- Kinase activity in bone metastases and epithelial circulating tumor cells is elevated -- BEVERLY, Mass., Jan. ...
-
--Rare parallel analyses of directly matched CTCs, utilizing TellBio’s TellDx platform, and ctDNA samples showing 95% concordance published in Breast Cancer Research and Treatment-- --Isolation of...
-
--Closes $5 million Series A financing-- --Appoints Pritesh J. Gandhi, PharmD, as Chief Executive Officer and Annie Partisano, PharmD, MS, as Senior Vice President and Head of Operations-- ...